Antibe Therapeutics Inc(Pre-Merger) T.ATE

The market is bored

[woundedknee]

Markets sometime gets bored with a stock like ATE, because it knows that the real deal is some time away and so the holders of the stock go elsewhere in the interim thinking they have time to get back in when the real deal takes place. Some stay and some go. Some win, because they stay, and some lose, because they weren't patient. Still long

[drippingsnot]

Agreed. Assuming the excitement will eventually return. I'm waiting for it ! -------- Good CEOs tend to outline their strategy for shareholders but they do it in a way that doesn't give too much information or hinder that strategy in any way.  Too much information is just as bad as not enough information so CEOs have to walk that fine-line. I think ATE does a good job with their

[TriumphSpitSix]

This inactivity is pretty typical between phases. The 8/4 corporate update also indicated reporting progress "over the coming months" so seems we're in a lull for a while. Just to help get things organized in my head, below are the upcoming catalysts as far as I can tell. Feel free to correct or add to these: 1. IND submission- Imminent? 2. IND "approval" - 30 days after

[TriumphSpitSix]

Forgot Citagenix....

[CalgaryATE]

#7 Report of preclinical studies for ATB-352 is Q3 2021 (as per the corporate update and also the latest MD&A). As to other catalysts... I'd say the news release for "hiring a US-based senior business development officer to execute the large market partnering." I don't necessarily think it'll spike the SP, but maybe 2-3 months after the hiring the SP might start to

[Pandora]

Why do they have to wait until April/May to start Phase 3?

[CalgaryATE]

It's in the latest MD&A that they expect to start phase 3 in late calendar Q1 2021 or early Q2 2021. I'm assuming it's for the following reasons (stated p.4 of the MD&A): "Additional Development Activities. Upon successful opening of the IND, the Company plans to commence an absorption, metabolism and excretion (AME) study in calendar Q4 2020 to satisfy its regulatory

[Blazesb]

So, i said it would be a year before phase 3 data would be the next repricing event--it depends if the long range studies highlighted above which conclude Q3 2021 will move the needle. Otherwise the 24-week phase 2 gi safety trials don't finish, optimistically, til Q2 2022.  Brother!  I hope Stern can make something stronger than lemonade out of the 'significant acetaminophin

[woundedknee]

Based on these timelines  i would say that the market will continue to be "bored". Can anyone think of any, (and I restate the word "any") events in the short or medium term that would push the sp up to the 50 to 60 cent mark that was mentioned in a previous post? Of course, not withstanding a consolidation. Does this company, right now, have enough going for it to be

[Forestview]

Well shareholders only approved a 5-to-1 or 10-to-1 split at this point, so they can't go higher.  So, Dan will need to do all in his power to drive the SP up to have a reverse split make sense for Nasdaq listing. Buckle in, this will be a long and boring drive through the Prairies.  (No offense to those that live in the Prairies).

[drippingsnot]

And I'm hoping that Dan won't need to do much dancing. Hoping events that unfold will take us to a better place. Interest may return quickly as the FDA anoints us as a Phase 3 and the company shows progress for their wonder-drug series. Waiting for news to surface.

[drippingsnot]

I think they do have a lot going for them but the outright sale and timing for that is a crapshoot. We don't know the discussions and we can't determine how desperate Big Pharma is to keep this product out of competitor's hands.  I'd love to be a fly right now. I think a clue going forward will be in the hiring of a partnering specialist - who will be doing the final

[TriumphSpitSix]

I think a few of the upcoming events I listed previously would work. If, instead of just allowing the 30-days to pass without objection, the FDA formally/expressly approves the company's IND application, which they can do at their discretion, that news should make for a nice pop. A licensing deal in one of the RoW countries for OPX, depending on dollar value should work too. Sale of Citagenix

[drippingsnot]

What makes it exciting ... is ... we don't have a clue what actually comes next. Keeping me on the edge of my seat. Will be upset if I'm sitting here ... waiting ... and nothing happens. : )

[woundedknee]

What makes me upset is looking at your alias, all the while trying to enjoy breakfast. I think it's disgusting and you should be ashamed.

[TriumphSpitSix]

What's wrong with "drippings not...?" I mean, yes, it's an incomplete sentence but is that really enough to cause morning nausea? I think maybe you're pregnant instead. quote=woundedknee] What makes me upset is looking at your alias, all the while trying to enjoy breakfast. I think it's disgusting and you should be ashamed.[/quote]

[Hideaway]

I think all posters agree with you and it we would all appreciate Dripping changing such a disgusting handle.

[TriumphSpitSix]

The discussion below on NASDAQ was pre-RS since we didn't know which of these events would occur first back in Sept. 2020 when I wrote it. Now that we've got a RoW deal in Asia and the price is moving up to a more appropriate level, it's time to move up to the big board, no additional RS needed. I still think they can uplist using the $2.00/sh criteria. I'd bet anything this is

[Actuarial]

There are three tiers in Nasdaq:The Nasdaq Global Select Market®, The Nasdaq Global Market® and The Nasdaq Capital Market®. Obviously, we would like to be in the top one, which requires $4USD initial listing price.